Glycosmis pentaphylla
Glycosmis pentaphylla
Glycosmis pentaphylla, a plant traditionally not extensively documented in medical practices, has shown promise in scientific research. Studies have indicated its potential for mitigating hepatic fibrosis through mechanisms that include restoring liver function and modulating inflammatory and oxidative stress responses. Additionally, network pharmacology analysis suggests possible anticancer activity via the identification of eight key alkaloids, with one specific alkaloid (KT32) demonstrating good cytotoxic activity against certain cancer cell lines. Furthermore, Glycosmis pentaphylla-functionalized selenium nanoparticles have shown potential in reducing fibrosis markers and improving hepatic function in animal models. No major safety concerns or recorded drug interactions are currently known for this plant.
- Best evidence
- D
- Cautions
- —
Informational only. Traditional use does not mean proven effectiveness. Evidence and safety vary — check the cited sources.
What the science says
- KT32 (10c), a dual HDAC and Topo II α inhibitor derived from Glycosmis pentaphylla alkaloids, showed good cytotoxic activity against certain cancer cell lines.
- Glycosmis pentaphylla methanolic extract mitigated CCl4-induced hepatic fibrosis in mice by restoring liver function, modulating inflammatory and oxidative stress responses.
- Glycosmis pentaphylla-functionalized selenium nanoparticles showed dose-dependent improvements in hepatic function and reduced fibrosis markers in mice with CCl4-induced liver damage.
- This study identified and quantified eight key alkaloids in Glycosmis pentaphylla, linking them to potential anticancer effects through network pharmacology.
Frequently asked questions
What is Glycosmis pentaphylla?
Glycosmis pentaphylla (Glycosmis pentaphylla) is a plant documented in FolkKB's traditional-medicine reference, drawn from sourced literature and cross-checked against the evidence.
What does the scientific evidence say about Glycosmis pentaphylla?
4 sourced findings are recorded for Glycosmis pentaphylla; the strongest carries evidence grade D. For example: KT32 (10c), a dual HDAC and Topo II α inhibitor derived from Glycosmis pentaphylla alkaloids, showed good cytotoxic activity against certain cancer cell lines.
How strong is the evidence for Glycosmis pentaphylla?
The strongest finding for Glycosmis pentaphylla carries evidence grade D — preliminary or traditional. Grades run A (strongest) to D (preliminary or traditional).
Is Glycosmis pentaphylla safe? What are the side effects?
No major safety issues are recorded for Glycosmis pentaphylla in our sources, but the data may be incomplete. Consult a qualified professional before use.
Does Glycosmis pentaphylla interact with medications?
No drug interactions are recorded for Glycosmis pentaphylla in our sources. This does not rule them out — check with a pharmacist.
Is Glycosmis pentaphylla a proven treatment?
No. FolkKB is informational only. Traditional use and early findings are not proof of efficacy or safety — consult a qualified professional and never self-treat.
Sources
- T2 Semisynthesis of Glycosmis pentaphylla Alkaloid Derivatives: Pyranoacridone-Hydroxamic Acid Cytotoxic Conjugates with HDAC and Topoisomerase II α Dual Inhibitory Activity. literature abstract metadata
- T2 Glycosmis pentaphylla mitigates CCl4-induced hepatic fibrosis in Swiss albino murine model through suppression of TGF-β/Smad2/3 signaling, oxidative stress and inflammatory responses: in-vivo and in-silico approach. literature abstract metadata
- T2 HPLC-PDA and LC-HRMS/MS-based quantitative and qualitative analysis of Glycosmis pentaphylla alkaloids, and investigation of their anticancer potential through network pharmacology. literature abstract metadata
- T2 Selenium Nanoparticles Functionalized with Glycosmis pentaphylla Extract Attenuate Hepatic Fibrosis Through Modulation of Oxidative Stress and Anti-Inflammatory Responses. literature abstract metadata